Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Can-Fite BioPharma Ltd. (CANF)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $405,000 | $674,000 | $743,000 | $810,000 | $853,000 | $763,000 | $2.0M | $3.8M | $789,000 | $165,000 |
| Research & development | $6.7M | $5.8M | $6.0M | $137,000 | $200,000 | $159,000 | $138,000 | $123,000 | $5.1M | $6.1M |
| Operating expenses | $10.4M | $8.8M | $8.9M | $10.9M | — | — | — | — | — | — |
| Operating income | −$9.9M | −$8.1M | −$8.2M | −$10.1M | −$12.8M | −$14.1M | −$12.0M | −$5.4M | −$7.2M | −$8.7M |
| EBITDAderived | −$9.9M | −$8.1M | −$8.2M | −$10.1M | −$12.8M | −$14.1M | −$12.0M | −$5.4M | — | — |
| Net income | −$9.8M | −$7.9M | −$7.6M | −$10.2M | −$12.6M | −$14.4M | −$12.6M | −$6.6M | −$6.3M | $8.3M |
| Basic EPSper diluted share | -$5.97 | -$10.86 | -$17.92 | -$0.01 | -$0.03 | -$0.04 | -$0.14 | -$0.17 | -$0.19 | $0.30 |
| Diluted EPSper diluted share | -$5.97 | -$10.86 | -$17.92 | -$0.01 | -$0.03 | -$0.04 | -$0.14 | -$0.17 | -$0.19 | $0.30 |